Imunon, Inc. (IMNN) Research

Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.

Market snapshot

Symbol
IMNN
Price
$1.82
Day change
-2.15%
Market cap
$4.6M
P/E ratio
-0.63x
52-week range
1.8-13.43478
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$10.00

Peer companies

  • AEON Biopharma, Inc. (AEON)
  • Bolt Biotherapeutics, Inc. (BOLT)
  • Cingulate Inc. (CING)
  • Cellectar Biosciences, Inc. (CLRB)
  • Cocrystal Pharma, Inc. (COCP)
  • Dogwood Therapeutics, Inc. (DWTX)
  • Evogene Ltd. (EVGN)
  • Marker Therapeutics, Inc. (MRKR)

Recent insider activity

  • Tardugno Michael H — A-Award (4089 shares) on 2026-06-05
  • Lindborg Stacy — A-Award (1593 shares) on 2026-06-05
  • Tardugno Michael H — A-Award (3484 shares) on 2026-05-22
  • Pellizzari Christine A — A-Award (5557 shares) on 2026-05-22
  • Dentzer James E — A-Award (11148 shares) on 2026-05-22

Open Imunon, Inc. (IMNN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.